Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7620)
All Articles published online
|
Publishing Process of This Article
|
Jul 15, 2017 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Filippatos TD, Filippas-Ntekouan S, Pappa E, Panagiotopoulou T, Tsimihodimos V, Elisaf MS. PCSK9 and carbohydrate metabolism: A double-edged sword. World J Diabetes 2017; 8(7): 311-316 [PMID: 28751953 DOI: 10.4239/wjd.v8.i7.311] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v8/i7/311.htm |
| Number | Citing Articles |
| 1 |
Theodosios D. Filippatos, Angelos Liontos, Eliza C. Christopoulou, Moses S. Elisaf. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. Current Vascular Pharmacology 2019; 17(4): 332 doi: 10.2174/1570161116666180209112351
|
| 2 |
Theodosios D. Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella, Moses S. Elisaf. Hypolipidemic Drugs and Diabetes Mellitus—Mechanisms and Data From Genetic Trials. Journal of Cardiovascular Pharmacology and Therapeutics 2018; 23(3): 187 doi: 10.1177/1074248418757011
|
| 3 |
Arturo Cesaro, Vanessa Bianconi, Felice Gragnano, Elisabetta Moscarella, Fabio Fimiani, Emanuele Monda, Olga Scudiero, Giuseppe Limongelli, Matteo Pirro, Paolo Calabrò. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long‐term inhibition. BioFactors 2020; 46(3): 367 doi: 10.1002/biof.1619
|
| 4 |
Theodosios D. Filippatos, Eliza C. Christopoulou, Moses S. Elisaf. Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. Current Opinion in Lipidology 2018; 29(4): 333 doi: 10.1097/MOL.0000000000000523
|
| 5 |
Junteng Zhou, Qi Zhang, Yushu Wang, Peijuan Gao, Decai Chen. The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis. Postgraduate Medicine 2018; 130(1): 129 doi: 10.1080/00325481.2018.1401421
|
| 6 |
Wan-chin Kuo, Jennifer M. Stevens, Anne L. Ersig, Heather M. Johnson, Tsan-Hua Tung, Lisa C. Bratzke. Does 24-h Activity Cycle Influence Plasma PCSK9 Concentration? A Systematic Review and Meta-Analysis. Current Atherosclerosis Reports 2020; 22(7) doi: 10.1007/s11883-020-00843-x
|
| 7 |
Robert R. Henry, Dirk Müller‐Wieland, Pam R. Taub, Maja Bujas‐Bobanovic, Michael J. Louie, Alexia Letierce, Henry N. Ginsberg. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. Diabetes, Obesity and Metabolism 2018; 20(7): 1632 doi: 10.1111/dom.13273
|
| 8 |
Lucia Del Vecchio, Ivano Baragetti, Francesco Locatelli. New agents to reduce cholesterol levels: implications for nephrologists. Nephrology Dialysis Transplantation 2019; doi: 10.1093/ndt/gfz013
|
| 9 |
Maurizio Balestrino, Enrico Adriano. Beyond sports: Efficacy and safety of creatine supplementation in pathological or paraphysiological conditions of brain and muscle. Medicinal Research Reviews 2019; 39(6): 2427 doi: 10.1002/med.21590
|
| 10 |
Theodosios D. Filippatos, Anastazia Kei, Moses S. Elisaf. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. Diseases 2017; 5(4): 21 doi: 10.3390/diseases5040021
|
| 11 |
Toshiyuki Nishikido, Kausik K. Ray. Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges. British Journal of Pharmacology 2021; 178(11): 2168 doi: 10.1111/bph.14851
|
| 12 |
V. Tsimihodimos, M. Elisaf. Effects of evolving lipid-lowering drugs on carbohydrate metabolism. Diabetes Research and Clinical Practice 2018; 137: 1 doi: 10.1016/j.diabres.2017.12.012
|
| 13 |
Sebastian Filippas-Ntekouan, Theodosios D. Filippatos, Moses S. Elisaf. SGLT2 inhibitors: are they safe?. Postgraduate Medicine 2018; 130(1): 72 doi: 10.1080/00325481.2018.1394152
|
| 14 |
Giovanni Ciccarelli, Saverio D’Elia, Michele De Paulis, Paolo Golino, Giovanni Cimmino. Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies. Diseases 2018; 6(1): 22 doi: 10.3390/diseases6010022
|
| 15 |
Rong-Bin Chen, Qi-Yu Wang, Yuan-Yuan Wang, Ya-Di Wang, Jiang-Hua Liu, Zhe-Zhen Liao, Xin-Hua Xiao. Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1094458
|
| 16 |
Wenbin Pan, Weiju Sun, Shuo Yang, He Zhuang, Huijie Jiang, Hong Ju, Donghua Wang, Ying Han. LDL-C plays a causal role on T2DM: a Mendelian randomization analysis. Aging 2020; 12(3): 2584 doi: 10.18632/aging.102763
|